Mind the gaps: Pharmacokinetic research to advance pediatric HIV/TB cotreatment and TB prevention

注意差距:推进儿科艾滋病毒/结核病联合治疗和结核病预防的药代动力学研究

基本信息

  • 批准号:
    10390005
  • 负责人:
  • 金额:
    $ 32.28万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2022
  • 资助国家:
    美国
  • 起止时间:
    2022-04-07 至 2027-01-31
  • 项目状态:
    未结题

项目摘要

PROJECT SUMMARY Tuberculosis (TB) is the leading cause of death among children with HIV, yet insufficient data are available on the pharmacokinetics (PK) of newer HIV/TB cotreatment and TB prevention strategies in children. Global expansion of dolutegravir use for young children has the potential to significantly improve HIV treatment outcomes, but there are no PK data to inform use of double-dose dolutegravir during rifampicin-containing HIV/TB cotreatment for children under 6 years of age. Further, multiple studies have shown that current WHO-recommended rifampicin dosages result in low concentrations in most children, and high-dose rifampicin may improve outcomes and shorten treatment duration in adults and children. Yet the impact of high-dose rifampicin on dolutegravir exposures has not been examined. Finally, it is well-established that treatment of latent TB infection (LTBI) significantly reduces incident TB among HIV-infected persons, yet this strategy is vastly underused in endemic settings. Short-course LTBI treatment regimens increase completion rates, but have not been studied among HIV-infected children receiving dolutegravir. To address these gaps in knowledge and provide needed PK and safety data to extend use of these promising strategies from adults to children, we will carry out two prospective PK studies to examine: (1) twice daily dolutegravir during both standard- and high-dose rifampicin, and (2) PK of dolutegravir during weekly rifapentine/isoniazid for TB prevention/LTBI treatment. To advance our understanding of underlying mechanisms of drug action we will also examine the impact of standard- and high-dose daily rifampicin and weekly rifapentine on the 4β-hydroxy-cholesterol to cholesterol ratio, an endogenous biomarker of CYP3A4 activity. This will provide critical pharmacodynamic (PD) data for use in population PK/PD models to quantify variability and inform optimal drug dosing in this vulnerable population of children. Nigeria is home to more children living with HIV than any other country in the world, and also bears one of the greatest burdens of incident TB. Since 2004, APIN Public Health Initiatives has provided HIV care and treatment to over 20,000 children in Nigeria and thus is uniquely positioned to support this vital PK research. This combination of studies addresses critical gaps in knowledge regarding PK and safety of newer drug combinations for HIV/TB cotreatment and TB prevention, findings that may inform WHO guidance on use in children, toward the goal of curbing TB’s devastating toll in this vulnerable population.
项目总结 结核病是感染艾滋病毒的儿童的主要死亡原因,但数据不足。 儿童HIV/TB联合治疗和结核病预防策略的药代动力学(PK)。全球 扩大幼儿多洛替格列韦的使用有可能显著改善艾滋病毒的治疗 结果,但没有PK数据表明在含有利福平的过程中使用双剂量多洛替格列韦 为6岁以下儿童提供艾滋病毒/结核病共同治疗。此外,多项研究表明,目前 世卫组织推荐的利福平剂量导致大多数儿童的低浓度,而高剂量 利福平可能会改善成人和儿童的预后,缩短治疗时间。然而,它的影响 大剂量利福平对多洛替格韦暴露的影响尚未得到检查。最后,众所周知, 治疗潜伏性结核病感染(LTBI)显著减少了艾滋病毒感染者中的结核病发病率,但 在地方病流行的环境中,这一策略被大大低估了。短程LTBI治疗方案增加 完成率,但尚未在接受多洛替格韦治疗的艾滋病毒感染儿童中进行研究。致信地址 这些知识上的差距并提供了必要的PK和安全数据来扩展这些有希望的应用 从成人到儿童,我们将进行两项前瞻性PK研究:(1)每天两次 在标准剂量和大剂量利福平期间服用多洛替格韦,以及(2)每周服用多洛替格韦。 利福喷丁/异烟肼用于结核病预防/LTBI治疗。 为了促进我们对药物作用的潜在机制的理解,我们还将研究 标准剂量和大剂量每日利福平和每周利福喷丁对4β-羟基胆固醇的影响 Ratio是细胞色素P450 3A4活性的内源性生物标志物。这将提供关键的药效学(PD)数据 在人群PK/PD模型中使用,以量化变异性并为此脆弱人群提供最佳药物剂量 儿童的数量。 尼日利亚是世界上感染艾滋病毒的儿童最多的国家,也是世界上 突发结核病的最大负担。自2004年以来,APIN公共卫生倡议提供了艾滋病毒护理和 在尼日利亚为20,000多名儿童提供治疗,因此在支持这项重要的PK研究方面处于独特的地位。 这项研究的结合解决了关于PK和新药安全性的知识的关键差距 艾滋病毒/结核病共同治疗和结核病预防的组合,可能为世卫组织在以下方面的使用提供指导的发现 儿童,朝着遏制结核病在这一脆弱人群中造成的毁灭性损失的目标前进。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Holly Elizabeth Rawizza其他文献

Holly Elizabeth Rawizza的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Holly Elizabeth Rawizza', 18)}}的其他基金

Mind the gaps: Pharmacokinetic research to advance pediatric HIV/TB cotreatment and TB prevention
注意差距:推进儿科艾滋病毒/结核病联合治疗和结核病预防的药代动力学研究
  • 批准号:
    10605218
  • 财政年份:
    2022
  • 资助金额:
    $ 32.28万
  • 项目类别:
Acquired HIV drug resistance among Nigerian children failing first-line ART: Implications for second-line dolutegravir use
一线抗逆转录病毒疗法失败的尼日利亚儿童获得了艾滋病毒耐药性:对二线多替拉韦使用的影响
  • 批准号:
    10483175
  • 财政年份:
    2021
  • 资助金额:
    $ 32.28万
  • 项目类别:
Acquired HIV drug resistance among Nigerian children failing first-line ART: Implications for second-line dolutegravir use
一线抗逆转录病毒疗法失败的尼日利亚儿童获得了艾滋病毒耐药性:对二线多替拉韦使用的影响
  • 批准号:
    10326999
  • 财政年份:
    2021
  • 资助金额:
    $ 32.28万
  • 项目类别:
Pharmacokinetic and Programmatic Evaluations to Optimize HIV/TB Co-Treatment Regimens in Children
优化儿童艾滋病毒/结核病联合治疗方案的药代动力学和规划评估
  • 批准号:
    10422433
  • 财政年份:
    2021
  • 资助金额:
    $ 32.28万
  • 项目类别:
Rifabutin pharmacokinetics and safety among HIV/TB coinfected infants receiving lopinavir
接受洛匹那韦治疗的 HIV/TB 合并感染婴儿中利福布汀的药代动力学和安全性
  • 批准号:
    9926695
  • 财政年份:
    2020
  • 资助金额:
    $ 32.28万
  • 项目类别:
Pharmacokinetic and Programmatic Evaluations to Optimize HIV/TB Co-Treatment Regimens in Children
优化儿童艾滋病毒/结核病联合治疗方案的药代动力学和规划评估
  • 批准号:
    9140789
  • 财政年份:
    2016
  • 资助金额:
    $ 32.28万
  • 项目类别:

相似海外基金

Enhancing Structural Competency in School-Based Health Centers to Address LGBTQ+ Adolescent Health Equity
增强校本健康中心的结构能力,以解决 LGBTQ 青少年健康公平问题
  • 批准号:
    10608426
  • 财政年份:
    2023
  • 资助金额:
    $ 32.28万
  • 项目类别:
Application and feasability of a brief digital screening tool to address parental and adolescent tobacco and electronic cigarette use in pediatric medical care - a pilot study
简短的数字筛查工具的应用和可行性,以解决儿科医疗中父母和青少年烟草和电子烟的使用问题 - 一项试点研究
  • 批准号:
    486580
  • 财政年份:
    2022
  • 资助金额:
    $ 32.28万
  • 项目类别:
    Studentship Programs
Co-design of an intervention to address alcohol use among adolescent boys and young men in Tanzania
共同设计一项干预措施,解决坦桑尼亚青春期男孩和年轻男性的饮酒问题
  • 批准号:
    MR/V032380/1
  • 财政年份:
    2022
  • 资助金额:
    $ 32.28万
  • 项目类别:
    Research Grant
Complex intervention to optimise adolescent BMI pre-conception to address the double burden of malnutrition: A RCT in rural and urban South Africa
优化青少年孕前体重指数以解决营养不良的双重负担的复杂干预措施:南非农村和城市的随机对照试验
  • 批准号:
    MR/V005790/1
  • 财政年份:
    2021
  • 资助金额:
    $ 32.28万
  • 项目类别:
    Research Grant
Application of a brief digital screening tool to address parental and adolescent tobacco and electronic cigarette use in pediatric medical care
应用简短的数字筛查工具来解决儿科医疗中父母和青少年烟草和电子烟的使用问题
  • 批准号:
    455984
  • 财政年份:
    2021
  • 资助金额:
    $ 32.28万
  • 项目类别:
    Operating Grants
Complex intervention to optimise adolescent BMI pre-conception to address the double burden of malnutrition: A RCT in rural and urban South Africa
优化青少年孕前体重指数以解决营养不良的双重负担的复杂干预措施:南非农村和城市的随机对照试验
  • 批准号:
    MR/V005790/2
  • 财政年份:
    2021
  • 资助金额:
    $ 32.28万
  • 项目类别:
    Research Grant
Development of the Cannabis Actions and Practices (CAP): A Parent-Focused Intervention to Address Adolescent Marijuana Use
大麻行动和实践 (CAP) 的发展:以家长为中心的干预措施,解决青少年大麻使用问题
  • 批准号:
    10057761
  • 财政年份:
    2020
  • 资助金额:
    $ 32.28万
  • 项目类别:
Development of the Cannabis Actions and Practices (CAP): A Parent-Focused Intervention to Address Adolescent Marijuana Use
大麻行动和实践 (CAP) 的发展:以家长为中心的干预措施,解决青少年大麻使用问题
  • 批准号:
    10213683
  • 财政年份:
    2020
  • 资助金额:
    $ 32.28万
  • 项目类别:
Targeted interventions to address the multi-level effects of gender-based violence on PrEP uptake and adherence among adolescent girls and young women in Kenya
有针对性的干预措施,以解决性别暴力对肯尼亚少女和年轻妇女接受和坚持 PrEP 的多层面影响
  • 批准号:
    9403567
  • 财政年份:
    2017
  • 资助金额:
    $ 32.28万
  • 项目类别:
Designing targeted interventions to address HIV vulnerabilities and improve clinical outcomes among conflict affected adolescent girls and young women under 25 in Northern Uganda
设计有针对性的干预措施,以解决乌干达北部受冲突影响的少女和 25 岁以下年轻妇女的艾滋病毒脆弱性并改善临床结果
  • 批准号:
    356145
  • 财政年份:
    2016
  • 资助金额:
    $ 32.28万
  • 项目类别:
    Operating Grants
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了